Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission

被引:83
作者
Loubser, Shayne
Balfe, Peter
Sherman, Gayle
Hammer, Scott
Kuhn, Louise
Morris, Lynn
机构
[1] Columbia Univ, Sergievsky Ctr, Coll Phys & Surg, New York, NY 10032 USA
[2] Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA
[3] Univ Witwatersrand, Johannesburg, South Africa
[4] Natl Hlth Lab Serv, Dept Mol Med & Haematol, Johannesburg, South Africa
[5] Columbia Univ, Dept Med, Coll Phys & Surg, Div Infect Dis, New York, NY 10032 USA
[6] Natl Inst Communicable Dis, AIDS Virus Res Unit, Johannesburg, South Africa
关键词
drug resistance; nevirapine; mother-to-child HIV transmission (MTCT);
D O I
10.1097/01.aids.0000222071.60620.1d
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: Single-dose nevirapine (sd-NVP) for prevention of mother-to-child HIV-1 transmission is associated with selection of resistant viral variants, particularly the Lysine (K) to Asparagine (N) mutation at codon 103 (K103N) of reverse transcriptase. As this may influence subsequent treatment responses, a better understanding of the dynamics of decay and persistence of this variant is needed. Design and methods: We measured the frequency of K103N mutants among a cohort of HIV-1-infected pregnant women recruited at an out-patient clinic in Johannesburg, South Africa. Samples taken 6 weeks, 3, 7 and 12 months after delivery from 67 HIV1-infected women who received sd-NVP during labor to prevent transmission were analyzed. Quantification of K103N mutants in maternal plasma viral RNA and cellular DNA was done using an allele-specific real-time polymerase chain reaction assay capable of detecting codons AAC and AAT if their frequency was > 0.002 of the total viral population. Results: Using the allele-specific assay, 87.1% (27/31) of RNA samples and 52.3% (23/44) of DNA samples collected 6 weeks after sd-NVP had detectable K103N variants. This declined to 65.4% (17/26), 38.9% (14/36), and 11.3% (6/53) in RNA at 3, 7 and 12 months respectively, and to 4.2% (2/48) in DNA at 12 months. Conclusions: K103N resistant variants v ere present in almost all women at 6 weeks post-sd-NVP but declined rapidly over time. Resistant variants were detected less frequently in cellular DNA with persistence in this compartment by 12 months Post-sd-NVP among only a minority. (c) 2006 Lippincott Williams & Wilkins
引用
收藏
页码:995 / 1002
页数:8
相关论文
共 19 条
[1]   Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants [J].
Collins, JA ;
Thompson, MG ;
Paintsil, E ;
Ricketts, M ;
Gedzior, J ;
Alexander, L .
JOURNAL OF VIROLOGY, 2004, 78 (02) :603-611
[2]   Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: A substudy of Pediatric AIDS Clinical Trials Group protocol 316 [J].
Cunningham, CK ;
Chaix, ML ;
Rekacewicz, C ;
Britto, P ;
Rouzioux, C ;
Gelber, RD ;
Dorenbaum, A ;
Delfraissy, JF ;
Bazin, B ;
Mofenson, L ;
Sullivan, JL .
JOURNAL OF INFECTIOUS DISEASES, 2002, 186 (02) :181-188
[3]   Characterization of nevirapine resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single-dose nevirapine (HIVNET 012) [J].
Eshleman, SH ;
Guay, LA ;
Mwatha, A ;
Brown, ER ;
Cunningham, SP ;
Musoke, P ;
Mmiro, F ;
Jackson, JB .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2004, 35 (02) :126-130
[4]   Impact of human immunodeficiency virus type 1 (HIV-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent HIV-1 vertical transmission (HIV Network for Prevention Trials 012 study) [J].
Eshleman, SH ;
Becker-Pergola, G ;
Deseyve, M ;
Guay, LA ;
Mracna, M ;
Fleming, T ;
Cunningham, S ;
Musoke, P ;
Mmiro, F ;
Jackson, JB .
JOURNAL OF INFECTIOUS DISEASES, 2001, 184 (07) :914-917
[5]   Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012) [J].
Eshleman, SH ;
Mracna, M ;
Guay, LA ;
Deseyve, M ;
Cunningham, S ;
Mirochnick, M ;
Musoke, P ;
Fleming, T ;
Fowler, MG ;
Mofenson, LM ;
Mmiro, F ;
Jackson, JB .
AIDS, 2001, 15 (15) :1951-1957
[6]   Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N Nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012 [J].
Flys, T ;
Nissley, DV ;
Claasen, CW ;
Jones, D ;
Shi, CJ ;
Guay, LA ;
Musoke, P ;
Mmiro, F ;
Strathern, JN ;
Jackson, JB ;
Eshleman, JR ;
Eshleman, SH .
JOURNAL OF INFECTIOUS DISEASES, 2005, 192 (01) :24-29
[7]   Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVMET 012 randomised trial [J].
Guay, LA ;
Musoke, P ;
Fleming, T ;
Bagenda, D ;
Allen, M ;
Nakabiito, C ;
Sherman, J ;
Bakaki, P ;
Ducar, C ;
Deseyve, M ;
Emel, L ;
Mirochnick, M ;
Fowler, MG ;
Mofenson, L ;
Miotti, P ;
Dransfield, K ;
Bray, D ;
Mmiro, F ;
Jackson, JB .
LANCET, 1999, 354 (9181) :795-802
[8]   Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission [J].
Jackson, JB ;
Becker-Pergola, G ;
Guay, LA ;
Musoke, P ;
Mracna, M ;
Fowler, MG ;
Mofenson, LM ;
Mirochnick, M ;
Mmiro, F ;
Eshleman, SH .
AIDS, 2000, 14 (11) :F111-F115
[9]   Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial [J].
Jackson, JB ;
Musoke, P ;
Fleming, T ;
Guay, LA ;
Bagenda, D ;
Allen, M ;
Nakabiito, C ;
Sherman, J ;
Bakaki, P ;
Owor, M ;
Ducar, C ;
Deseyve, M ;
Mwatha, A ;
Emel, L ;
Duefield, C ;
Mirochnick, M ;
Fowler, MG ;
Mofenson, L ;
Miotti, P ;
Gigliotti, M ;
Bray, D ;
Mmiro, F .
LANCET, 2003, 362 (9387) :859-868
[10]   Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated [J].
Johnson, JA ;
Li, JF ;
Morris, L ;
Martinson, N ;
Gray, G ;
McIntyre, J ;
Heneine, W .
JOURNAL OF INFECTIOUS DISEASES, 2005, 192 (01) :16-23